{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit could not be determined within 95% confidence interval due to low enrollment.The limited sample size is not enough to accurately estimate the upper limit of the confidence interval. A larger sample size would be needed to get a more reliable estimate.","groupId":"OG000","lowerLimit":"9.69","upperLimit":"NA","value":"30.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"The time from the start of treatment to death from any cause with last date known alive as censoring date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine:\n\nAt phase II, Bendamustine will be administered at 90mg/m\\^2 by IV over 1 hour at days 1 and 4 of the 28 day treatment cycle.\n\nDoxorubicin:\n\nPegylated liposomal doxorubicin at phase II will be administered at 30 mg/m2 by IV over 1 hour,at day 4 of the 28 day treatment cycle.\n\nBortezomib:\n\nBortezomib at Phase II will be administered at 1.3 mg/m2 by IV bolus or SQ injection on days 1, 4, 8, and 11 of the 28 day cycle.","id":"OG000","title":"Phase II : Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin."}],"paramType":"MEDIAN","populationDescription":"Two subjects never received treatment. Therefore, they were not included in any assessment of objectives.","reportingStatus":"POSTED","timeFrame":"From C1D1 up to a maximum of 54 months or until death","title":"Phase II: Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}